SLGL

Peers: PVLA VRCA PTHS ARQT ACRS DERM EVMN BFRI KRYS DRMA

Index	-
Market Cap	220.63M
Enterprise Value	173.47M
Income	-16.34M
Sales	1.79M
Book/sh	14.69
Cash/sh	14.64
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	28
IPO	Feb 01, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	123.26
P/B	4.59
P/C	4.60
P/FCF	-
EV/EBITDA	-
EV/Sales	96.91
Quick Ratio	10.37
Current Ratio	10.37
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-5.64
EPS next Y	-9.06
EPS next Q	-2.07
EPS this Y	-253.14%
EPS next Y	-16.88%
EPS next 5Y	-
EPS past 3/5Y	30.15% 29.88%
Sales past 3/5Y	70.92% 17.19%
EPS Y/Y TTM	-361.11%
Sales Y/Y TTM	-92.50%
EPS Q/Q	-127.01%
Sales Q/Q	-96.58%
Earnings	Aug 20 BMO
EPS/Sales Surpr.	52.12% 688.00%

Insider Own	59.73%
Insider Trans	3.44%
Inst Own	45.92%
Inst Trans	9.47%
ROA	-35.11%
ROE	-40.85%
ROIC	-33.79%
Gross Margin	-
Oper. Margin	-989.97%
Profit Margin	-910.14%
SMA20	-3.97%
SMA50	-4.48%
SMA200	-8.65%
Trades

Shs Outstand	3.27M
Shs Float	1.32M
Short Float	11.05%
Short Ratio	2.70
Short Interest	0.15M
52W High	97.97 -31.21%
52W Low	28.81 133.91%
Volatility	6.86% 6.57%
ATR (14)	4.29
RSI (14)	47.02
Beta	1.26
Rel Volume	0.00
Avg Volume	53.97K
Volume	0

Perf Week	-1.91%
Perf Month	12.86%
Perf Quarter	-17.78%
Perf Half Y	-6.79%
Perf YTD	59.92%
Perf Year	72.35%
Perf 3Y	343.36%
Perf 5Y	-25.63%
Perf 10Y	-
Recom	1.00
Target Price	152.50
Prev Close	67.39
Price	67.39
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-26	Initiated	Cantor Fitzgerald	Overweight
Jun-24-26	Initiated	Mizuho	Outperform	$285
May-29-26	Initiated	TD Cowen	Buy
Aug-19-24	Downgrade	Raymond James	Strong Buy → Outperform	$6 → $4
Oct-21-22	Resumed	Jefferies	Hold	$5.50
Dec-31-19	Reiterated	JMP Securities	Mkt Outperform	$20 → $33
Dec-31-19	Reiterated	H.C. Wainwright	Buy	$23 → $26

Sep-30-26 09:14AM	Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026 (GlobeNewswire)
Sep-17-26 08:30AM	Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome (GlobeNewswire)
Aug-20-26 08:30AM	Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
Jul-22-26 10:34AM	What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin's Rare-Obesity Opportunity (FinanceWire) -6.06%
May-28-26 08:00AM	Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
09:38PM	Loading…
Mar-23-26 09:38PM	Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering (GlobeNewswire) -9.28% +20.86%
Mar-19-26 08:53AM	Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025 (GlobeNewswire) +8.46%
Mar-12-26 11:55AM	This Under-the-Radar Stock Has Surged 1,300% Over the Past Year (Barchart) -9.52%
Dec-17-25 07:00AM	Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease (GlobeNewswire)
Nov-20-25 07:30AM	Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Sep-04-25 07:00AM	Sol-Gel Announces Health Canada Approval of EPSOLAY (GlobeNewswire) +19.66%
Aug-15-25 07:00AM	Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-23-25 07:15AM	Sol-Gel Reports First Quarter 2025 Results (GlobeNewswire)
May-01-25 07:00AM	Sol-Gel Announces Reverse Share Split (GlobeNewswire)
Apr-17-25 08:40AM	Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S. (GlobeNewswire) +14.58%
12:00PM	Loading…
Nov-20-24 12:00PM	SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know (Zacks)
07:00AM	Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement (GlobeNewswire)
Nov-15-24 08:10AM	Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Sep-17-24 09:55AM	SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-27-24 12:00PM	All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy (Zacks) +10.22%
Aug-17-24 11:27AM	UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-16-24 08:10AM	Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
07:00AM	Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Jul-25-24 07:00AM	Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa (GlobeNewswire) -32.85%
Jul-15-24 07:00AM	Sol-Gel Technologies Announces Management Realignment (GlobeNewswire) -8.13%
May-28-24 07:00AM	Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice (GlobeNewswire)
May-20-24 01:53PM	SLGL Stock Earnings: Sol-Gel Technologies Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -6.00%
08:10AM	Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
06:00AM	Loading…
May-16-24 06:00AM	Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO in the Mainland of China, Hong Kong, Macau, Taiwan and Israel (GlobeNewswire) +5.65%
Apr-01-24 07:00AM	Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve Cream (GlobeNewswire)
Mar-13-24 07:00AM	Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments (GlobeNewswire)
Nov-30-23 07:00AM	Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study (GlobeNewswire)
Nov-28-23 08:06AM	Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610 (GlobeNewswire)
Nov-09-23 07:00AM	Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-23 06:43AM	Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies (Zacks)
Oct-30-23 10:05AM	3 Generic Drug Stocks to Watch Amid Improving Market Prospects (Zacks)
Aug-30-23 08:00AM	Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 08:15AM	Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-21-23 06:04AM	Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Top Key Executive Moshe Arkin is the most upbeat insider, and their holdings increased by 15% last week (Simply Wall St.) +6.20%
Jun-06-23 07:30AM	Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada (Business Wire)
Jun-02-23 06:09AM	Shareholders in Sol-Gel Technologies (NASDAQ:SLGL) are in the red if they invested five years ago (Simply Wall St.)
May-12-23 08:25AM	Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-22-23 08:19AM	Companies Like Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Invest In Growth (Simply Wall St.)
Mar-22-23 05:43AM	Load Up, Says Raymond James About These 3 Strong Buy Stocks (TipRanks) +14.69%
Mar-20-23 07:00AM	Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-12-23 08:23AM	Sol-Gel Technologies Full Year 2022 Earnings: Misses Expectations (Simply Wall St.)
Mar-10-23 08:15AM	Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments (GlobeNewswire)
Feb-27-23 06:02AM	Could The Market Be Wrong About Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Its Attractive Financial Prospects? (Simply Wall St.) +6.02%
Feb-23-23 02:32PM	The Top 7 Penny Stocks to Invest in for the Long-Term (InvestorPlace) -6.35%
Jan-27-23 07:29AM	Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings (GlobeNewswire)
07:00AM	Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million (GlobeNewswire)
Dec-08-22 06:16AM	Zacks Industry Outlook Highlights Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies (Zacks)
Dec-07-22 10:52AM	3 Generic Drug Stocks to Watch Amid Inflation Pressures (Zacks)
Nov-10-22 04:00AM	Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-22 03:03PM	Sol-Gel Technologies (NASDAQ:SLGL) investors are sitting on a loss of 45% if they invested a year ago (Simply Wall St.)
Oct-03-22 08:00AM	Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development (GlobeNewswire)
Sep-19-22 01:00PM	Are Strong Financial Prospects The Force That Is Driving The Momentum In Sol-Gel Technologies Ltd.'s NASDAQ:SLGL) Stock? (Simply Wall St.)
Sep-12-22 04:30AM	Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel (Zacks)
Sep-09-22 12:13PM	3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure (Zacks)
Aug-04-22 06:00AM	Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -6.64%
Jun-01-22 08:00AM	Sol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference (GlobeNewswire)
May-27-22 11:45AM	Investors in Sol-Gel Technologies (NASDAQ:SLGL) have unfortunately lost 43% over the last year (Simply Wall St.) +6.53%
May-17-22 07:00AM	Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-13-22 07:00AM	Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +6.00%
Apr-25-22 07:00AM	Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY® (GlobeNewswire) -7.61%
Apr-14-22 08:30AM	Sol-Gel Technologies Announces the Commercial Availability of TWYNEO® (GlobeNewswire) +9.94%
Apr-12-22 11:26AM	Are Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? (Simply Wall St.)
Mar-30-22 07:00AM	Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments (GlobeNewswire)
Mar-25-22 11:00AM	Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA (GlobeNewswire)
Dec-22-21 04:05PM	Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference (GlobeNewswire)
Dec-21-21 07:00AM	Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY® (GlobeNewswire)
Nov-30-21 08:27AM	Shareholders in Sol-Gel Technologies (NASDAQ:SLGL) have lost 23%, as stock drops 12% this past week (Simply Wall St.) +9.10%
Nov-11-21 07:00AM	Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Nov-09-21 07:05AM	Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-21 07:30AM	Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million (GlobeNewswire)
Oct-01-21 12:14PM	Will Sol-Gel Technologies (NASDAQ:SLGL) Spend Its Cash Wisely? (Simply Wall St.)
Sep-22-21 07:30AM	Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference (GlobeNewswire) -6.09%
Sep-09-21 08:30AM	Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-17-21 01:30PM	What Is The Ownership Structure Like For Sol-Gel Technologies Ltd. (NASDAQ:SLGL)? (Simply Wall St.)
Aug-04-21 07:05AM	Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire) -5.67%
Jul-27-21 10:26AM	Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris (Benzinga)
09:15AM	Sol-Gel Technologies Announces FDA Approval of TWYNEO® (GlobeNewswire)
Jul-20-21 07:05AM	Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021 (GlobeNewswire)
Jun-28-21 05:10AM	Sol-Gel Announces Pipeline Update and Future Development Plans (GlobeNewswire) -6.79%
05:00AM	Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States (Business Wire)
May-27-21 07:00AM	Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference (GlobeNewswire)
May-18-21 09:27AM	Does Sol-Gel Technologies' (NASDAQ:SLGL) Share Price Gain of 23% Match Its Business Performance? (Simply Wall St.)
May-13-21 07:05AM	Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) +15.19%
Apr-28-21 08:41PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sol-Gel Technologies Ltd. - SLGL (Newsfile) -6.33%
Apr-27-21 02:20PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Sol-Gel Technologies Ltd. (SLGL) Investigation (ACCESSWIRE) -12.66%
10:02AM	Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY® (GlobeNewswire)
Mar-19-21 06:56AM	Sol-Gel Technologies (NASDAQ:SLGL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Mar-10-21 10:29AM	Raymond James: These 3 Stocks Are Poised to Surge by at Least 50% (TipRanks) +10.79%
Mar-04-21 07:05AM	Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update (GlobeNewswire) -8.42%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Sep 10 '26	Buy	66.80	1,631	108,943	538,507	Sep 14 05:23 PM
Opaleye Management Inc.	10% Owner	Sep 11 '26	Buy	65.94	1,493	98,456	540,000	Sep 14 05:23 PM
Opaleye Management Inc.	10% Owner	Sep 08 '26	Buy	68.82	3,861	265,703	533,779	Sep 09 07:18 PM
Opaleye Management Inc.	10% Owner	Sep 09 '26	Buy	68.70	3,097	212,779	536,876	Sep 09 07:18 PM
Opaleye Management Inc.	10% Owner	Sep 04 '26	Buy	69.14	3,018	208,677	529,918	Sep 09 07:18 PM
Opaleye Management Inc.	10% Owner	Sep 02 '26	Buy	68.95	900	62,054	526,900	Sep 03 04:05 PM
Opaleye Management Inc.	10% Owner	Sep 01 '26	Buy	69.52	783	54,434	526,000	Sep 03 04:05 PM
Opaleye Management Inc.	10% Owner	Aug 28 '26	Buy	69.32	35,113	2,434,156	520,000	Aug 31 06:24 PM
Opaleye Management Inc.	10% Owner	Aug 31 '26	Buy	68.27	5,217	356,170	525,217	Aug 31 06:24 PM
Opaleye Management Inc.	10% Owner	Aug 12 '26	Buy	71.50	951	67,996	494,887	Aug 14 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 14 '26	Buy	73.43	920	67,556	493,936	Jul 15 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 13 '26	Buy	73.89	775	57,263	493,016	Jul 15 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 08 '26	Buy	73.69	300	22,107	492,012	Jul 10 04:41 PM
Opaleye Management Inc.	10% Owner	Jul 10 '26	Buy	73.95	229	16,935	492,241	Jul 10 04:41 PM
Opaleye Management Inc.	10% Owner	Jul 02 '26	Buy	71.97	1,400	100,759	491,712	Jul 02 06:11 PM
Opaleye Management Inc.	10% Owner	Jul 01 '26	Buy	71.99	312	22,461	490,312	Jul 02 06:11 PM
Opaleye Management Inc.	10% Owner	May 20 '26	Buy	64.43	1,563	100,712	490,000	May 22 04:05 PM
Opaleye Management Inc.	10% Owner	May 13 '26	Buy	66.87	1,937	129,527	488,437	May 14 04:05 PM
Opaleye Management Inc.	10% Owner	May 12 '26	Buy	67.98	1,500	101,975	486,500	May 14 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 24 '26	Buy	72.00	39,665	2,855,880	485,000	Mar 24 04:05 PM
Yosef Itzik	Officer	Mar 11 '26	Proposed Sale	88.70	142	12,595		Mar 12 07:11 AM
Yosef Itzik	Officer	Feb 25 '26	Proposed Sale	87.63	1,556	136,352		Feb 26 06:21 AM
Yosef Itzik	Officer	Feb 23 '26	Proposed Sale	83.98	1,170	98,257		Feb 24 07:41 AM
Opaleye Management Inc.	10% Owner	Feb 13 '26	Buy	63.00	291	18,333	450,335	Feb 18 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 02 '26	Buy	58.00	100	5,800	450,944	Feb 04 04:05 PM
Opaleye Management Inc.	10% Owner	Jan 27 '26	Buy	57.05	100	5,705	449,944	Jan 29 04:16 PM
Opaleye Management Inc.	10% Owner	Jan 22 '26	Buy	56.57	2,173	122,922	448,693	Jan 23 05:42 PM
Opaleye Management Inc.	10% Owner	Jan 23 '26	Buy	55.98	1,151	64,434	449,844	Jan 23 05:42 PM
Yosef Itzik	Officer	Jan 14 '26	Proposed Sale	62.94	713	44,876		Jan 15 06:54 AM
Opaleye Management Inc.	10% Owner	Jan 02 '26	Buy	41.92	2,394	100,348	447,133	Jan 06 04:05 PM
Opaleye Management Inc.	10% Owner	Jan 05 '26	Buy	42.98	198	8,510	447,331	Jan 06 04:05 PM
Opaleye Management Inc.	10% Owner	Dec 30 '25	Buy	41.99	35,169	1,476,627	421,242	Dec 31 05:45 PM
Opaleye Management Inc.	10% Owner	Dec 31 '25	Buy	41.99	22,497	944,744	443,739	Dec 31 05:45 PM
Opaleye Management Inc.	10% Owner	Dec 29 '25	Buy	41.85	8,638	361,534	386,073	Dec 31 05:45 PM
Opaleye Management Inc.	10% Owner	Dec 26 '25	Buy	41.68	1,626	67,765	377,435	Dec 29 04:05 PM
Opaleye Management Inc.	10% Owner	Dec 22 '25	Buy	41.15	1,019	41,936	375,549	Dec 29 04:05 PM
Opaleye Management Inc.	10% Owner	Dec 23 '25	Buy	41.66	260	10,832	375,809	Dec 29 04:05 PM
Opaleye Management Inc.	10% Owner	Dec 17 '25	Buy	40.37	2,735	110,412	374,530	Dec 19 04:05 PM
Opaleye Management Inc.	10% Owner	Dec 12 '25	Buy	40.00	87	3,480	371,795	Dec 16 04:05 PM
Opaleye Management Inc.	10% Owner	Dec 05 '25	Buy	39.50	444	17,537	371,408	Dec 09 04:12 PM
Opaleye Management Inc.	10% Owner	Dec 08 '25	Buy	39.77	300	11,932	371,708	Dec 09 04:12 PM
Opaleye Management Inc.	10% Owner	Dec 01 '25	Buy	37.37	4,340	162,167	368,440	Dec 03 05:39 PM
Opaleye Management Inc.	10% Owner	Dec 03 '25	Buy	37.81	2,524	95,443	370,964	Dec 03 05:39 PM
Opaleye Management Inc.	10% Owner	Nov 26 '25	Buy	40.00	943	37,720	364,100	Nov 26 04:05 PM
Opaleye Management Inc.	10% Owner	Nov 24 '25	Buy	35.50	6	213	363,157	Nov 26 04:05 PM
Opaleye Management Inc.	10% Owner	Nov 20 '25	Buy	35.83	5,784	207,244	363,151	Nov 21 04:05 PM

Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

Chief Financial OfficerMr. Eyal Ben-Or

Chief Operating OfficerDr. Itzik Yosef

Chief Business OfficerMr. Michael Glezin

CEO & Executive ChairmanMr. Moshe Arkin

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Sol-Gel Technologies Ltd

Upgrade your Finviz experience